KR102373215B1 - 인자 Xa 유도체의 제조 - Google Patents

인자 Xa 유도체의 제조 Download PDF

Info

Publication number
KR102373215B1
KR102373215B1 KR1020197000840A KR20197000840A KR102373215B1 KR 102373215 B1 KR102373215 B1 KR 102373215B1 KR 1020197000840 A KR1020197000840 A KR 1020197000840A KR 20197000840 A KR20197000840 A KR 20197000840A KR 102373215 B1 KR102373215 B1 KR 102373215B1
Authority
KR
South Korea
Prior art keywords
seq
acid sequence
amino acid
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197000840A
Other languages
English (en)
Korean (ko)
Other versions
KR20190019134A (ko
Inventor
마크 카바즈
파멜라 비 콘리
건민 루
Original Assignee
포톨라 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102373215(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 포톨라 파마슈티컬스, 인코포레이티드 filed Critical 포톨라 파마슈티컬스, 인코포레이티드
Publication of KR20190019134A publication Critical patent/KR20190019134A/ko
Application granted granted Critical
Publication of KR102373215B1 publication Critical patent/KR102373215B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197000840A 2016-06-17 2017-06-19 인자 Xa 유도체의 제조 Active KR102373215B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
US62/351,841 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (2)

Publication Number Publication Date
KR20190019134A KR20190019134A (ko) 2019-02-26
KR102373215B1 true KR102373215B1 (ko) 2022-03-10

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197000840A Active KR102373215B1 (ko) 2016-06-17 2017-06-19 인자 Xa 유도체의 제조

Country Status (21)

Country Link
US (4) US10604748B2 (enExample)
EP (3) EP3926044B1 (enExample)
JP (4) JP6959268B2 (enExample)
KR (1) KR102373215B1 (enExample)
CN (3) CN110167575B (enExample)
AU (3) AU2017283720C1 (enExample)
CL (2) CL2018003654A1 (enExample)
CO (1) CO2019000120A2 (enExample)
DK (1) DK3472314T3 (enExample)
EA (1) EA037815B1 (enExample)
ES (2) ES2875538T3 (enExample)
HU (1) HUE054597T2 (enExample)
IL (1) IL263591B2 (enExample)
MX (1) MX2018015873A (enExample)
PE (1) PE20190661A1 (enExample)
PH (1) PH12018502614A1 (enExample)
PL (1) PL3472314T3 (enExample)
PT (1) PT3472314T (enExample)
SG (1) SG11201810915QA (enExample)
SI (1) SI3472314T1 (enExample)
WO (1) WO2017219034A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3604510T3 (pl) * 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
EP2948168B1 (en) * 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
EP3926044B1 (en) * 2016-06-17 2025-06-04 Alexion Pharmaceuticals, Inc. Preparation of factor xa derivatives
US12195774B2 (en) 2018-06-19 2025-01-14 Alexion Pharmaceuticals, Inc. Antidotes to factor XA inhibitors
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
WO2014116275A1 (en) 2013-01-24 2014-07-31 Portola Pharmaceuticals, Inc. INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
US20150025011A1 (en) 2009-07-15 2015-01-22 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
CN101304971B (zh) 2005-11-08 2011-09-07 米伦纽姆医药公司 Xa因子抑制剂n-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基-苯甲酰胺的医药盐和多晶型
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PL3604510T3 (pl) * 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
EP2861614B1 (en) * 2012-06-14 2016-11-30 Portola Pharmaceuticals, Inc. METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN112195169A (zh) * 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
KR20250150675A (ko) * 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형
EP3926044B1 (en) * 2016-06-17 2025-06-04 Alexion Pharmaceuticals, Inc. Preparation of factor xa derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
US20150025011A1 (en) 2009-07-15 2015-01-22 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
WO2014116275A1 (en) 2013-01-24 2014-07-31 Portola Pharmaceuticals, Inc. INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Protein Science, 2009, Vol.18, pp.1023-1032

Also Published As

Publication number Publication date
MX2018015873A (es) 2019-08-12
CN116425860A (zh) 2023-07-14
CL2018003654A1 (es) 2019-01-25
JP6959268B2 (ja) 2021-11-02
DK3472314T3 (da) 2021-07-26
PE20190661A1 (es) 2019-05-08
JP2026010692A (ja) 2026-01-22
JP7273918B2 (ja) 2023-05-15
PH12018502614A1 (en) 2019-09-30
IL263591B (en) 2022-11-01
EA201990052A1 (ru) 2019-05-31
JP2019528242A (ja) 2019-10-10
US20200208131A1 (en) 2020-07-02
WO2017219034A2 (en) 2017-12-21
US20240076642A1 (en) 2024-03-07
JP2022000477A (ja) 2022-01-04
WO2017219034A3 (en) 2019-03-14
HUE054597T2 (hu) 2021-09-28
KR20190019134A (ko) 2019-02-26
CO2019000120A2 (es) 2019-03-29
ES3038834T3 (en) 2025-10-15
EP3472314A2 (en) 2019-04-24
CN116425860B (zh) 2025-03-04
CN110167575B (zh) 2024-03-15
CN118271391A (zh) 2024-07-02
IL263591A (en) 2019-02-03
PL3472314T3 (pl) 2021-11-22
CA3027457A1 (en) 2017-12-21
US11845966B2 (en) 2023-12-19
IL263591B2 (en) 2023-03-01
CN110167575A (zh) 2019-08-23
CL2020001733A1 (es) 2020-09-25
SG11201810915QA (en) 2019-01-30
JP2023086970A (ja) 2023-06-22
PT3472314T (pt) 2021-06-18
AU2017283720A1 (en) 2019-01-03
EP4588932A3 (en) 2025-10-01
US20170369862A1 (en) 2017-12-28
EP3926044A1 (en) 2021-12-22
SI3472314T1 (sl) 2021-11-30
EP4588932A2 (en) 2025-07-23
AU2023200825A1 (en) 2023-03-16
EP3472314A4 (en) 2020-01-22
US10954504B2 (en) 2021-03-23
EP3926044B1 (en) 2025-06-04
EA037815B1 (ru) 2021-05-25
AU2017283720C1 (en) 2024-07-25
US20210348149A1 (en) 2021-11-11
EP3472314B1 (en) 2021-05-05
ES2875538T3 (es) 2021-11-10
AU2026206233A1 (en) 2026-08-13
AU2023200825B2 (en) 2026-04-23
BR112018075964A2 (pt) 2019-04-02
AU2017283720B2 (en) 2022-11-17
US10604748B2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
AU2023200825B2 (en) Preparation of factor Xa derivatives
JP7000394B2 (ja) 補因子の非存在下で凝固活性を有する、及び／又は、第ｉｘ因子凝固活性が増加した第ｉｘ因子変異体、並びに、出血性疾患を処置するためのその使用
RU2731507C1 (ru) Gla домены в качестве нацеливающих агентов
WO2011135308A1 (en) Conjugated blood coagulation factor viia
TW201521761A (zh) 重組體ｆｖｉｉｉ調配物
EP3419650B1 (en) Lyophilized formulations for factor xa antidote
CA3027457C (en) Preparation of factor xa derivatives
CA2722230A1 (en) Dry transglutaminase composition
HK40065948A (en) Preparation of factor xa derivatives
HK40006502B (en) Preparation of factor xa derivatives
BR122025008348A2 (pt) Produto polipeptídico expressado a partir de um construto de polinucleotídeo, composição farmacêutica e uso da referida composição farmacêutica
BR112018075964B1 (pt) Método para preparar um produto de polipeptídeo expressado a partir de um construto de polinucleotídeo, composição farmacêutica e uso da referida composição farmacêutica
JP2008189574A (ja) 膵島移植補助薬剤
HK40001910B (en) Lyophilized formulations for factor xa antidote

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190109

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200422

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210224

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211027

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210224

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211027

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210623

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20211227

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20211125

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20211027

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210623

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220307

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220307

End annual number: 3

Start annual number: 1

PG1601 Publication of registration